LimSS,VosT,FlaxmanAD,DanaeiG,ShibuyaK,Adair Rohani H, 2012.a systematic analysis for the Global Burden of Disease Study 2010, 380 2224 -60
StellaMG,KyvelouGP,VyssoulisEA,KarpanouDN,AdamopoulosAI,ZervoudakiPG, 2006.Effects of antihypertensive treatment withangiotensin ii receptor blockers on lipid profile: an open multi-drug comparison trial,Hellenic J Cardiol 47 21 -8
YuQ,LarsonDF,SlaybackD,LundeenTF,BaxterJH,WatsonRR, 2004.Characterization of high-salt and high-fat diets on cardiac and vascular function in mice,Cardiovascc. Toxicol 4 37 -46
PohanK., 2006.Lipid-lowering drugs,Cell Mol Life Sci 63 1165 -78
GhibaudiL,CookJ,FrarleyC,Van HeekM., 2002.Fat inktake affects adiposity comorbid factors, and energy metabolism of Sprague-Dawley rats,Obes Res 10 956 -63
ColpoA. LDL, 2005.Cholesterol: Bad cholesterol, or bad science?,JPANDS 10 83 -9
LarosaJC,HeJ,VupputuriS, 1999.Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials,JAMA 282 2340 -6
FadicR,JohnsDR,BealMF,HowellN, 1997.free radicals in neurodegerative disease, 19 537 -5
SeverP, 1997.Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker,J Hum Hypertens 11 91 -5
BrunnerHR, 1997.The new angiotensin ii receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations,Am J Hypertens 10 311 -7
Marino,MariaR,VachharajaniNN, 2002.Pharmacokinetics of irbesartan are not altered in special populations,J CardiovascPharmacol 40 112 -22
TronquetC,MandrayM,MasseD,MiscoriaG,BergerY., 1996.Excretion and metabolism following single oral a d m i n i s t ra t i o n ( 1 0 m g / k g ) o f i r b e s a r ta n t o Macacafascicularis monkeys,CA ISSX 10 321 -
VachharajaniNNE,ShyuCW,SmithAR,GreeneSD, 1998.The effects of age and gender on the pharmacokinetics of irbesartan,Br J ClinPharmacol 46 611 -3
RiveiroA,MosqueraA,AlonsoM,CalvoC, 2002.Angiotensin II type 1 receptor blocker irbesartan ameliorates vascular function in spontaneously hypertensive rats regardless ofoestrogen status,J Hypertens 20 1365 -72
WaeberB,BrunnerHR, 2003.Angiotensin 11-antagonists: A new class of antihypertensive agent,Br J Clinprac 50 265 -8
BarrerasA,TurnerGC, 2003.Angiotensin II receptor blockers,BaylUniv Med 16 123 -6
RongX,LiY,ZhaoM,KusakabeT,TomitaT,MurrayM, 2010.Irbesartan treatment upregulates hepatic expression of PPAR alpha and its target genes in obese koletsky rats: a link to amelioration of hypertriglyceridemia,Br J Pharmacol 160 1796 -807
DerosaG,FogariE,AngeloAD,CircirotAFG,SalvadeoSAT,RagonesiPD, 2007.Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone,J Clin Phar Ther 32 261 -8
YutingC,RongliangZ,ZhongjianiJ, 1990.Flavanoids as superoxide scavengers and as antioxidants,Free Rad Biol Med 9 19 -
PadillaE,SanzM,GanadoP,TejerinaTY, 2002.Effects of irbesartan and losartan in cholesterol-fed rabbits,Clin Invest Arterioscl 14 230 -8
BimenyaSG,KasoloJ,OkwiLA,OthienoI,OchiengJ,KaluleB, 2010.Determination of LDL-cholesterol: direct measurement by homogenous assay versus Friedewald calculation among Makerere University undergraduate fasting student,Int J Biol Chem 4 464 -70
MaxwellKN,SoccioRE,DuncanEM,SehayekE,Jl, 2003.Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice,Lipid Res 44 2109 -19
ShimamuraM,NakagamiH,MoritaniT,NakagamiF,OsakoKM, 2011.Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels,Experimental and Therapeutic Medicine 2 957 -61
GiordanoM,MatsudaM,SandersL,CanessaML,DeFronzo RA, 1995.Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension,Diabetes 44 665 -71
HashimotoM,KagotaS,KubotaY,KatakuraM,EnkhjargalB,GamohS, 2007.Effect of amlodipine, a calcium channel antagonist, on cholesterol levels in the cerebral cortex and hippocampus of obese and hypertensive SHR,Clin Exp Pharmacol 34 35 -6
KirkKJ, 1999.Angiotensin-II Receptor Antagonists: Their Place in Therapy,Am Fam Physician 59 3140 -8
SanzM,GanadoP,TejerinaT, 2002.Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterolfed rabbits,Eur J Pharmacol 442 99 -106
MarkhamA,GoaKL.,Valsartan, 1997.A review of its pharmacology and therapeutic use in essential hypertension,Drugs 54 299 -311
MiwaK,MurakamH,MasakiK,IwasakiM,YoshimuraM.,JHypertens, 1998.In vitro hepatic metabolism of candesartan to its inactive metabolite, CV-15959, 16 128 -
OparilS,WilliamsD,ChrysantSG, 2001.Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension,J Clin Hypertens 3 283 -91